Deutsche Bank Reiterates a 'Hold' on Chelsea Therapeutics (CHTP); Saga With FDA Takes New Turn
Tweet Send to a FriendGet Alerts CHTP Hot Sheet
Price: $1.88 -0.53%
Rating Summary:
2 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Rating Summary:
2 Buy, 2 Hold, 0 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 11 | Down: 35 | New: 23
Trade CHTP Now!
Deutsche Bank reiterates a 'Hold' on Chelsea Therapeutics (NASDAQ: CHTP).
Deutsche analyst said, "FDA is concerned that the suggested trial amendments to Study 306B, which is evaluating Northera vs. placebo in NOH patients, were based on Chelsea having unblinded the trial. In speaking with Chelsea, this is not the case and the trial remains blinded. The FDA is taking a theoretical approach that Chelsea may have received hints of data from its CRO that would allow it to design the trial to work. The FDA has stated that Chelsea's 306b would not be adequate for approval due to this theoretical risk."
Overall, the Deutsche analyst would feel more comfortable if a trial on the higher-end or longer than 3 months was implemented
For an analyst ratings summary and ratings history on Chelsea Therapeutics click here. For more ratings news on Chelsea Therapeutics click here.
Shares of Chelsea Therapeutics closed at $1.46 yesterday, with a 52 week range of $1.05-$6.06.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
Deutsche analyst said, "FDA is concerned that the suggested trial amendments to Study 306B, which is evaluating Northera vs. placebo in NOH patients, were based on Chelsea having unblinded the trial. In speaking with Chelsea, this is not the case and the trial remains blinded. The FDA is taking a theoretical approach that Chelsea may have received hints of data from its CRO that would allow it to design the trial to work. The FDA has stated that Chelsea's 306b would not be adequate for approval due to this theoretical risk."
Overall, the Deutsche analyst would feel more comfortable if a trial on the higher-end or longer than 3 months was implemented
For an analyst ratings summary and ratings history on Chelsea Therapeutics click here. For more ratings news on Chelsea Therapeutics click here.
Shares of Chelsea Therapeutics closed at $1.46 yesterday, with a 52 week range of $1.05-$6.06.
Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW
*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here
You May Also Be Interested In
- Morgan Stanley Says Tesla (TSLA) 'Top Pick in U.S. Autos'
- Supernus (SUPN) PT Trimmed at Jefferies, But Survey Shows Significant Market Opportunity
- Wells Fargo Upgrades Rosetta Resources (ROSE) to Outperform, Shares Attractive
Create E-mail Alert Related Categories
Analyst Comments, FDARelated Entities
Deutsche Bank
Login with Facebook
Sign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
